Group 1 - The 2025 Prix Galien USA nominations were announced, with Signet Therapeutics being the only Chinese biopharmaceutical company nominated for the Best Biotechnology Award for its drug SIGX1094R, a targeted therapy for diffuse gastric cancer [1][2] - SIGX1094R is the world's first drug developed using the "organoid + AI" platform and has received IND approvals from both the FDA and China's National Medical Products Administration, along with orphan drug designation and fast track designation from the FDA [1] - The drug is currently undergoing Phase I clinical trials at Peking University Cancer Hospital and is expected to enter Phase II clinical trials by the end of 2025 [1] Group 2 - Signet Therapeutics is the world's first "organoid + AI" innovative drug development company, recognized as a national high-tech enterprise and a specialized and innovative enterprise [2] - The founding team of the company comes from prestigious institutions such as Harvard University, MIT, and the Chinese Academy of Sciences, with over 20 groundbreaking research papers published in high-impact journals in the field of gastric and esophageal cancer [2] - The company has completed nearly 220 million yuan in financing and project funding, holding over 40 core intellectual properties [2]

希格生科（深圳）有限公司作为全球首家结合类器官与AI进行肿瘤创新靶向药研发的企业，希格生科 展示了其基于类器官+AI开发的临床首款弥漫性胃癌靶向药FAK抑制剂的最新进展，该药物已获批进入 一期临床，显示了初步的有效性和安全性。 清源至芯（深圳）生物科技有限公司依托自主研发的类器官3D打印+AI核心技术平台，展示了其"关键 装备+核心材料+技术服务"的多维产品矩阵，已与多家国内顶尖三甲医院及科研院校达成战略合作。 深圳市创心医疗科技有限公司带来了全球首创的A型夹层全腔内重建系统，该系统已完成临床试验，随 访结果良好，并已取得FDA突破性器械认证。 【深圳商报讯】（首席记者谢惠茜）7月24日，"深圳创投日"活动走进粤港澳大湾区国家技术创新中心 国际总部（以下简称"国际总部"），南方创投网生命健康科技成果转化项目专场路演成功举办。 据悉，该活动旨在通过产融对接，加速生命健康领域科技成果的商业化进程，推动深圳乃至大湾区生命 健康产业集群的高质量发展。 "深圳创投日"作为深圳市推动创业投资服务现代产业体系升级和新质生产力发展的重要平台，自启动以 来便以其广泛的影响力和显著的成效，成为深圳创新创业领域的标志性活动。此次活 ...